Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sequential Release of mRNA Complex and T Cells by a Double-Layered Implantable Scaffold for Combination Therapy of Head and Neck Squamous Cell Carcinoma.

International journal of nanomedicine·2026

Same author

Current Advancements in the Arsenal for Spinal Cord Injury Repair: Novel Drug Formulations.

International journal of nanomedicine·2026

Same author

Hydrogels for Cancer Immunotherapy: Strategies From Construction to Application.

MedComm·2026

Same author

An Implantable Double-Layered Spherical Scaffold Depositing Gene and Cell Agents to Facilitate Collaborative Cancer Immunotherapy.

ACS nano·2025

Same author

A Novel Systemic siDR6 Delivery System Based on DP7-C for the Treatment of Metastatic Lung Cancer.

International journal of nanomedicine·2025

Same author

Controlled release of MIF siRNA and GDNF protein from a photocurable scaffold efficiently repairs spinal cord injury.

MedComm·2025

Same journal

Vertically Stacked Indium Gallium Zinc Oxide-Based Three-Dimensional Integrated Circuits.

ACS nano·2026

Same journal

Tunable Nanoparticle Thin-Film Reveals Distance Dependence of Auger-Mediated Radiation Enhancement in Diffuse Midline Glioma.

ACS nano·2026

Same journal

G-Quadruplex Network Engineering in Ionogels: Realizing Robust Biosensing Interfaces for Plant Electrophysiology.

ACS nano·2026

Same journal

Announcing the 2026 <i>ACS Nano</i> Lectureship and <i>ACS Nano</i> Impact Award Laureates.

ACS nano·2026

Same journal

Ultrafast Self-Assembly of Zeolitic Imidazolate Framework-8 Enables Antibody Orientation for Ultrasensitive Lateral Flow Immunoassays.

ACS nano·2026

Same journal

Interfacial Salt Engineering with Alkali and Ammonium Additives for Stable Pure-Blue Perovskite Light-Emitting Diodes and Micropatterned Displays.

ACS nano·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 13, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Chimeric Antigen Receptor-Engineered Cell Membrane-Coated Nanoparticles Promote Dual-Targeted mRNA-Based Cancer Gene

Sibei Lei^1,2, Jingmei Li¹, Manfang Zhu³

¹Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.

|April 14, 2025

Summary

This summary is machine-generated.

Chimeric antigen receptor (CAR)-coated nanoparticles enhance mRNA delivery for cancer therapy. This CAR-inspired platform improves tumor targeting and suppression, offering a promising strategy for mRNA-based gene therapy.

Keywords:

cell membrane chimeric antigen receptor-T-cell therapy immunogenic cell death mRNA delivery tumor-targeted delivery

More Related Videos

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

Related Experiment Videos

Last Updated: May 13, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

Area of Science:

Biotechnology
Oncology
Nanomedicine

Background:

Messenger RNA (mRNA) therapy shows promise in cancer treatment but faces challenges with targeted delivery, leading to off-target effects.
Chimeric antigen receptor (CAR) technology enables MHC-independent targeting of cancer cells.
Cancer cell membrane-coated nanoparticles offer a platform for gene engineering and targeted delivery.

Purpose of the Study:

To develop a CAR-inspired, cancer cell membrane-coated nanoparticle platform for enhanced tumor-targeted mRNA delivery.
To evaluate the efficacy of this novel platform in delivering mRNA for cancer therapy.

Main Methods:

Engineered CAR molecules onto cancer cell membranes to create CAR-CT26 cells.
Extracted CAR-CT26 membranes (CARM) and coated them onto lipid nanoparticle (LNP)-mRNA to form CARM@LNP-mRNA.
Assessed mRNA transfection efficiency and tumor suppression in HER2+ CT26 cancer models.

Main Results:

CARM@LNP-mRNA demonstrated enhanced mRNA transfection efficiency in HER2-overexpressing CT26 cells.
Systemic administration of CARM@LNP-mRNA showed superior tumor targeting and suppression compared to non-CAR coated nanoparticles.
Effective tumor suppression was observed in both subcutaneous and peritoneal metastasis models.

Conclusions:

CAR-coated cancer cell membrane nanoparticles (CARM@LNP) represent a feasible and effective platform for mRNA-based gene therapy.
This dual tumor-targeted strategy holds significant potential for improving cancer treatment outcomes.
CARM@LNP-mRNA offers a promising approach for systemic tumor-targeted therapeutic delivery.